Adam Waldman - TG Therapeutics Chief Commercial Officer
| TGTX Stock | USD 33.36 0.01 0.03% |
Executive
Mr. Adam Waldman is Chief Commercial Officer of the company. He joins TG Therapeutics with more than 20 years of experience in the biotechnology and life science industries. Most recently, Mr. Waldman served as the Head of US HematologyOncology Marketing at Celgene Corporation where he spent the past 13 years in various roles of increasing responsibility in sales, marketing and new product strategy. Adam brings extensive experience and a proven track record of success building high performing teams and launching transformational products in both hematology and oncology. Prior to Celgene, Mr. Waldman was at Schering Plough where he was responsible for coordinating the global marketing strategy for multiple oncology products since 2018.
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560 |
| Phone | 212 554 4484 |
| Web | https://www.tgtherapeutics.com |
TG Therapeutics Management Efficiency
At this time, TG Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2025, whereas Return On Capital Employed is likely to drop 0.07 in 2025. At this time, TG Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 383.9 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 7.6 M in 2025. TG Therapeutics' management efficiency ratios could be used to measure how well TG Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Patrick MBA | Exelixis | 48 | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Mark MBA | X4 Pharmaceuticals | 61 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| Friso Postma | BioXcel Therapeutics | N/A | |
| Andrew Peters | Exelixis | N/A | |
| Geoffrey Barker | Viking Therapeutics | N/A | |
| Shannon Kelley | Madrigal Pharmaceuticals | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Melita Jung | Terns Pharmaceuticals | 48 | |
| Dana Aftab | Exelixis | 61 | |
| Scott Gangloff | Akero Therapeutics | 51 | |
| MS MBA | PDS Biotechnology Corp | 59 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Anne MD | Exelixis | N/A | |
| Ronald Filippo | Madrigal Pharmaceuticals | N/A | |
| Jeffrey Jasper | Terns Pharmaceuticals | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.0805 | ||||
| Return On Asset | -7.0E-4 |
TG Therapeutics Leadership Team
Elected by the shareholders, the TG Therapeutics' board of directors comprises two types of representatives: TG Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TGTX. The board's role is to monitor TG Therapeutics' management team and ensure that shareholders' interests are well served. TG Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TG Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Corp CFO | ||
| Jenna Bosco, Director of Investor Relations | ||
| Adam Waldman, Chief Commercial Officer | ||
| Sean CPA, Corporate CFO | ||
| Michael Esq, CEO Chairman |
TGTX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TG Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0805 | ||||
| Return On Asset | -7.0E-4 | ||||
| Profit Margin | (0.05) % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 5.11 B | ||||
| Shares Outstanding | 155.66 M | ||||
| Shares Owned By Insiders | 9.50 % | ||||
| Shares Owned By Institutions | 66.50 % | ||||
| Number Of Shares Shorted | 27.63 M | ||||
| Price To Earning | (4.14) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.